These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10530699)

  • 1. Daily cost of newer glaucoma agents.
    Stewart WC; Hudgins AC; Pruitt CA; Sine C
    J Ocul Pharmacol Ther; 1999 Oct; 15(5):379-88. PubMed ID: 10530699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost considerations of the new fixed combinations for glaucoma medical therapy.
    Ventura MP; Saheb NE; Solari HP; Saraiva VS; Vianna RN; Burnier MN
    J Clin Pharm Ther; 2005 Jun; 30(3):251-4. PubMed ID: 15896242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.
    Bateman DN; Clark R; Azuara-Blanco A; Bain M; Forrest J
    Br J Ophthalmol; 2002 May; 86(5):551-4. PubMed ID: 11973253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost considerations of medical therapy for glaucoma.
    Fiscella RG; Geller JL; Gryz LL; Wilensky J; Viana M
    Am J Ophthalmol; 1999 Oct; 128(4):426-33. PubMed ID: 10577583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy cost considerations for glaucoma.
    Fiscella RG; Green A; Patuszynski DH; Wilensky J
    Am J Ophthalmol; 2003 Jul; 136(1):18-25. PubMed ID: 12834665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of glaucoma medications: a 3-year review.
    Vold SD; Riggs WL; Jackimiec J
    J Glaucoma; 2002 Aug; 11(4):354-8. PubMed ID: 12169974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily cost of glaucoma medications in China.
    Gao Y; Wu L; Li A
    J Glaucoma; 2007; 16(7):594-7. PubMed ID: 18091176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
    Razeghinejad MR; Sawchyn AK; Katz LJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):959-68. PubMed ID: 20307220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
    Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
    Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.